Video Tag: idiopathic pulmonary fibrosis

New regenerative lung therapy begins phase 1 trials | CMR316 & IPF treatment

The Calibr-Skaggs Institute for Innovative Medicines, part of Scripps Research, has begun testing a new regenerative lung therapy called CMR316. This inhaled treatment could change the way we treat lung diseases like idiopathic pulmonary fibrosis (IPF) and potentially even chronic obstructive pulmonary disease by stimulating stem cells to restore damaged lung tissue. In this phase 1 clinical trial, they're checking the safety and effects of this once-weekly drug in both healthy volunteers and IPF patients.